PT - JOURNAL ARTICLE AU - Weinstock, Christof AU - Flegel, Willy A AU - Srivastava, Kshitij AU - Kaiser, Sabine AU - Schrezenmeier, Hubert AU - Tsamadou, Chrysanthi AU - Ludwig, Carolin AU - Jahrsdörfer, Bernd AU - Bovin, Nicolai V AU - Henry, Stephen M TI - Erytra Blood Group Analyser and Kode Technology testing of SARS-CoV-2 antibodies among convalescent patients and vaccinated individuals AID - 10.1101/2021.08.26.21262219 DP - 2021 Jan 01 TA - medRxiv PG - 2021.08.26.21262219 4099 - http://medrxiv.org/content/early/2021/08/28/2021.08.26.21262219.short 4100 - http://medrxiv.org/content/early/2021/08/28/2021.08.26.21262219.full AB - Surveillance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic requires tests to monitor antibody formation and prevalence. We detected SARS-CoV-2 antibodies using red cells coated by Kode technology with short peptides derived from the SARS-CoV-2 spike protein. Such modified red cells, called C19-kodecytes, can be used as reagent cells in any manual or automated column agglutination assay. We investigated the presence of SARS-CoV-2 antibodies in 130 samples from COVID-19 convalescent plasma donors using standard manual technique, two FDA authorized ELISA assays and a virus neutralisation assay. The sensitivity of the C19-kodecyte assay was 88%, comparable to the anti-SP and anti-NCP ELISAs (86% and 83%) and the virus neutralisation assay (88%). The specificity of the C19-kodecyte assay was 90% (anti-SP 100% and anti-NCP 97%). Likewise, 231 samples from 73 vaccinated individuals were tested with an automated analyser and we monitored the appearance and persistence of SARS-CoV-2 antibodies. The C19-kodecyte assay is a robust tool for SARS-CoV-2 antibody detection. Automated blood group analyser use enables large-scale SARS-CoV-2 antibody testing for vaccination monitoring in population surveys.Competing Interest StatementThe employer of CW has received honoraria for presentations from Grifols S.A., Barcelona, Spain. SH and NB are stockholders in Kode Biotech Ltd the patent owner of Kode Technology. WAF, KS, SK, HS, CT, and BJ have no conflicts of interest. Clinical TrialThis study was not registered as a clincal study by the local ethics committee.Funding StatementWAF was supported by the Intramural Research Program (project ID ZIC CL002128) of the NIH Clinical Center at the National Institutes of Health. Development and supply of FSL constructs was supported the New Zealand Ministry of Business, Innovation & Employment COVID-19 Innovation Acceleration Fund, contract CIAF 0490.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics board of the University of UlmAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated during and/or analyzed during the current study are available upon request by contact the corresponding author.